跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 218 条关于
“61Cu-TraceNet”
全部
218
临床试验
87
药物
113
机构
1
资讯
17
去年
NUCLIDIUM's Copper-Based PET Tracer Shows Promise in Phase I/II Trial for Neuroendocrine Tumor Detection
去年
NUCLIDIUM's Copper-Based Radiotracer Shows Enhanced Imaging Performance in First Prostate Cancer Patient
去年
Nuclidium Raises $99M Series B to Advance Copper-Based Radiopharmaceutical Platform
11个月前
NUCLIDIUM Secures US Patent Protection for Copper-Based FAP-Targeting Radiotheranostics Platform
去年
Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA Gain FDA Fast Track Designations for Prostate Cancer
去年
BRACELET-1 Trial Shows Promise for Oncolytic Virus Pelareorep in HR+ Breast Cancer
2年前
Clarity Pharmaceuticals' 67Cu-SAR-bisPSMA Shows Promise in mCRPC Trial
去年
Clarity Pharmaceuticals and Nucleus RadioPharma Collaborate on 67Cu-SAR-bisPSMA Phase 3 Trial
2年前
Clarity's 64Cu-SAR-bisPSMA Shows Promise in Detecting Prostate Cancer Recurrence in COBRA Trial
去年
Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA Evaluated in Head-to-Head Prostate Cancer Imaging Trial
第 1 页,共 2 页
上一页
下一页